DERMATITIS, ATOPIC

This study looks at teenagers aged 12 to 17 who have severe atopic dermatitis (eczema) with intense itching but only a mild to moderate rash. They are being treated with dupilumab (Dupixent), a standard medication. The goal is to see how well dupilumab controls itching, improves …

This early-stage study tests a new drug called DCY636 for safety and tolerability in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The trial has two parts: a single dose in healthy adults and multiple doses in eczema patients. It aims to gather…

This study tests an injectable drug called amlitelimab for people aged 12 and older with moderate-to-severe eczema that hasn't improved with other treatments. Participants will also use standard steroid creams. The goal is to see if the drug can clear or nearly clear the skin com…

This study tests an experimental drug called JNJ-95597528 in 180 adults with moderate to severe atopic dermatitis (eczema). Participants will receive either the drug or a placebo to see if it improves skin symptoms by at least 75% after 12 weeks. The goal is to control the diseas…

This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). About 280 participants will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching over 24 weeks. The goal is to find a saf…

This study is tracking 150 adults and teens with moderate-to-severe eczema who have already tried up to two biologic drugs without success. Researchers want to see how well the oral medication abrocitinib (Cibinqo) works in real-world settings. The main goals are to measure impro…

This study is monitoring the safety and effectiveness of the prescription drug Cibinqo (abrocitinib) in people with moderate to severe atopic dermatitis (a type of eczema). About 1,100 participants in Korea will take the tablet as prescribed by their doctor and be observed for on…

This Phase 3 trial tests a drug called 611 in 180 Chinese teenagers (ages 12–17) with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. Participants receive injections every two weeks for up to a year. The main go…

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how much their skin improves over 12 months using standard eczema severity scores. The goal is to see how well the drug works …

This study examines how common eczema treatments, including antibiotics and bleach baths, change the types and amounts of bacteria on the skin. Researchers will compare people with eczema to healthy volunteers. The goal is to understand the skin microbiome better, not to test a n…